Corticotropin Zinc Hydroxide

Summary

Corticotropin Zinc Hydroxide (CHEMBL1201609) is an approved unknown targeting MC2R.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Targets: 1 (MC2R)

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201609
Name	Corticotropin Zinc Hydroxide
Type	Unknown
Max phase	4

Also known as: Corticotropin zinc hydroxide, Corticotropin-zinc hydroxide, Corticotropina hidroxido de zinc, Corticotropine hydroxyde de zinc, Cortrophin-zinc, CORTICOTROPIN ZINC HYDROXIDE

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
MC2R	MC2 receptor	Agonist		0%	Q01718

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): MC2R.

Top Reactome pathways

10 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	1	MC2R
Disease	1	MC2R
Signaling by GPCR	1	MC2R
Class A/1 (Rhodopsin-like receptors)	1	MC2R
Peptide ligand-binding receptors	1	MC2R
GPCR downstream signalling	1	MC2R
G alpha (s) signalling events	1	MC2R
GPCR ligand binding	1	MC2R
Defective ACTH causes obesity and POMCD	1	MC2R
Diseases of metabolism	1	MC2R

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	1
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
signal transduction	1
neuropeptide signaling pathway	1

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

1 molecules share ≥1 primary target. Top 1 by shared-target count:

Molecule	Source	Status	Shared targets
ATUMELNANT	ChEMBL	Phase 2	MC2R